EnWave Closes CDN$12.0 Million Bought Deal Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES


EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or the "Company")
today announced that it has closed the bought deal private placement previously
announced on January 18, 2011, including the full exercise of the over-allotment
option. The offering was led by Canaccord Genuity Corp., on behalf of a
syndicate of underwriters that included Laurentian Bank Securities and Clarus
Securities Inc. (the "Underwriters"), under which the Underwriters purchased
6,706,000 Units (the "Units") at a price of CDN$1.80 per Unit for aggregate
gross proceeds of CDN$12,070,800 (the "Offering"). Each Unit consists of one
common share of the Company and one-half of one common share purchase warrant
(each whole warrant, a "Warrant"). Each Warrant entitles the holder to subscribe
for one additional common share for a period of 18 months from the closing of
the Offering at an exercise price of CDN$2.25. The Company intends to use the
net proceeds of the Offering for general working capital purposes.


EnWave paid the Underwriters a cash commission equal to 7% of the gross proceeds
raised under the Offering and issued to the Underwriters warrants (the
"Underwriter's Warrant") equal to 10% of the number of Units sold under the
Offering. Each Underwriter's Warrant is exercisable to purchase one common share
at a price of $1.80 for a period of 18 months from closing of the Offering. The
securities issued by EnWave in connection with this Offering are subject to a
4-month "hold period" as prescribed by the TSX Venture Exchange and applicable
Canadian securities laws.


This news release does not constitute an offer to sell, or a solicitation of an
offer to buy, any of the securities in the United States. The securities have
not been and will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state securities laws and
may not be offered or sold within the United States or to U.S. Persons unless
registered under the U.S. Securities Act and applicable state securities laws or
an exemption from such registration is available.


About EnWave 

Using proprietary technologies developed in conjunction with the University of
British Columbia, EnWave is commercializing a new method for dehydrating food
and biological materials using Radiant Energy Vacuum ("REV") technology under
its nutraREV(TM), powderREV(TM), quantaREV(TM), bioREV(TM), freezeREV(TM) and
MIVAP(TM) brands. REV technology combines microwave energy transfer under vacuum
to dehydrate and alter structures and drive chemical reactions, thereby creating
unique product characteristics for both food products and medical applications
that include fruit, vegetables, probiotics, enzymes, proteins, food cultures,
vaccines and antibodies. More information about EnWave is available at
www.enwave.net.


EnWave Corporation

John McNicol, President & Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may
contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's strategy
for growth, product development, market position, expected expenditures and
financial results are forward-looking statements. These statements are not a
guarantee of future performance and involve a number of risks, uncertainties and
assumptions. There is no guarantee that the Company's REV technology can or will
improve processes in the target industry; even if the Company's REV technology
can be used as described in this document, there is no guarantee that such use
will result in orders for the Company's REV technology. All figures comparing
REV technologies to freeze drying or other dehydration technologies are provided
as examples of data obtained through the Company's own scientific and testing
programs; each product must be tested individually to determine the benefits of
using REV.
(TSXV:REV)
過去株価チャート
から 5 2024 まで 6 2024